Quantcast

Industry news that matters to you.  Learn more

Definiens Launches Immunoprofiling Panel to Rapidly Screen Tissue Samples for Immune Responses

Definiens, the pioneer in Tissue Phenomics solutions for diagnostics development and commercialization, recently announced the release of a new service, the Immunoprofiling Panel, to enable pharmaceutical companies, companion diagnostic developers and academic research centers working in immuno-oncology to quickly screen their target biomarkers and measure immune response.

Leading Oncology Researchers Address Growing Need for Assessing Tumor Microenvironment in Cancer Research

Key professionals in leading biopharma organizations attended The International Symposium for Tissue Phenomics™ in October 2014 to discuss the latest developments in cancer research and big data. Hosted by Definiens, the global leader in Tissue Phenomics for oncology diagnostics, the event drew key industry professionals and featured speakers from cutting edge organizations such as INSERM, National Cancer Institute, Kimmel Cancer Center, Providence Health Services, OncoMed Pharmaceuticals and University Medical Center Heidelberg. Presentations highlighted novel, important approaches in cancer research for the development of companion diagnostics, analysis of data, and validation of assays used to drive therapies.

Definiens to Host the First International Symposium for Tissue Phenomics This Fall

Definiens, the global leader in Tissue Phenomics™ for oncology diagnostics, recently announced that registration is now open for the company’s inaugural conference, The International Symposium for Tissue Phenomics. Alongside genomics, Tissue Phenomics is a key driver in the growth of personalized medicine, and the symposium brings together thought leaders from around the globe on companion diagnostics, immunotherapy, and tissue-based patient stratification for personalized medicine. The Symposium will begin with a keynote lecture from Nobel Laureate, Gerd Binnig, Ph.D., discussing his approach to uncovering novel diagnostics through using big data in tissue.

Definiens Signs Agreement with Clarient to Offer Validated Solutions for Routine Clinical Pathology Testing

Definiens, the global leader in image analysis for digital pathology and diagnostics recently announced the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer. Definiens’ proprietary Cognition Network Technology® is core to automatically classify and quantitate key tissue features as part of Clarient’s Scope IA Platform offering to its pathology customers.

Definiens and Metamark Enter Multi-Year Deal for Prostate Cancer Prognostic Test

Definiens, the global leader in image analysis for digital pathology and diagnostics, and Metamark Genetics, a privately-held biotechnology company developing novel tests aimed at improving cancer care, recently announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark™ prostate cancer prognostic test.